Finnish researchers use heat to activate cellular cleanup in aging eyes
In 2016, a Japanese cell biologist named Yoshinori Ohsumi stood on a stage in Stockholm and accepted the Nobel Prize in Medicine. He had spent decades studying something most people had never heard of: autophagy, the way cells eat their own garbage. The discovery was beautiful and abstract. It described a process inside every living cell, a kind of molecular housekeeping that keeps things clean. But for most of the world, the connection to daily life was invisible. It was a prize for basic science, not for a cure.
Nine years later, a team at Aalto University in Finland has built a bridge between that abstract prize and a very concrete problem[2]. They have designed a treatment that uses heat to wake up the same cellular cleanup system in the aging eye. The goal is to stop dry age-related macular degeneration before it steals central vision. The method is simple in concept: warm the tissue at the back of the eye by a few degrees, trigger the cell’s own repair mechanisms, and let the body fix itself.
The furnace is not a furnace. It is a beam of near-infrared light, carefully controlled, aimed at a spot behind the retina. The temperature must rise only slightly. Too hot, and the tissue burns. Too cold, and nothing happens. The researchers built a system that monitors the heat in real time, measuring the electrical response of the retina as it warms. This is not guesswork. It is precision.
Professor Ari Koskelainen leads the research. He describes the problem in a way that makes the disease feel like a slow mechanical failure. With age, the protective machinery inside cells weakens. Free oxygen radicals, which are normal byproducts of metabolism, begin to damage proteins. The proteins misfold, clump together, and form fatty deposits called drusen. Those drusen are the hallmark of dry AMD. They accumulate under the retina, especially in the macula, the region responsible for sharp central vision. Over years, the buildup interferes with the cells that keep the retina alive. Vision fades. Faces become blurry. Reading becomes impossible.
The standard approach to this disease has been reactive. Doctors wait until damage is done, then try to manage the consequences. There are few treatments for the early stages. Most patients are told to watch their diet, take certain supplements, and return for checkups. The Aalto team is trying something different. They want to intervene before the damage becomes permanent. They want to give aging cells a gentle shock, a wake-up call that reminds them how to clean house.
Heat shock proteins are the first responders. When a cell senses a rise in temperature, it produces these proteins to help other proteins fold correctly. Misfolded proteins are dangerous. They aggregate, form toxic clumps, and disrupt normal function. Heat shock proteins grab them, refold them, or tag them for destruction. This is a natural defense, but it weakens with age. The Aalto treatment is designed to re-activate it.
Then comes autophagy. This is the system that Ohsumi mapped out. It is a cellular garbage disposal. A membrane forms around damaged components, enzymes break them down, and the raw materials are recycled. In dry AMD, the garbage accumulates faster than the disposal can handle it. The treatment aims to speed up the disposal.
Koskelainen says the team was able to activate both systems with controlled heat shocks. Not just one. Both. This is important because the disease involves multiple failures. The treatment does not target a single symptom. It targets the underlying weakness in the cell’s defense network.
The metaphor that runs through this research is the furnace. Not a destructive furnace, but a forge. Heat is applied not to destroy, but to reshape. The cell is like a piece of metal that has grown brittle with age. A controlled temperature rise, carefully applied, restores some of its original strength. The cell does not become young again. But it becomes more capablee of handling the stress that comes with time.
Testing has moved through animals. Mice and pigs have received the treatment, and the results show that the protective response can be triggered in retinal tissue. The next step is human trials, which are scheduled to begin in Finland in spring 2026. The first phase is about safety. Researchers need to know that the heat does not harm the eye. Only after that will they test whether it actually slows or stops the disease.
The treatment is not a one-time fix. The response begins to fade after a few days. This means patients might need regular sessions, like a maintenance therapy. It could become something people visit the clinic for every few weeks or months, a brief exposure to infrared light that keeps the cellular cleanup running.
This is not the only light-based treatment in development. In the United States, the FDA has authorized a device called the Valeda Light Delivery System, which uses photobiomodulation for certain patients with dry AMD[6]. That approach uses light to stimulate cellular activity without significant heating. The Aalto method is different. It relies on a controlled temperature rise, not just light exposure. Both are part of a broader shift in how researchers think about dry AMD. For years, the disease was considered untreatable in its early stages. That assumption is being challenged.
The Aalto study was published in Nature Communications in October 2025[1]. The researchers have also started a company called Maculaser to commercialize the technology[7]. Koskelainen says that if everything goes well, the method could be used in hospital eye clinics within three years. The goal is to make it available at local ophthalmologists, not just specialized research centers.
But the promise is still ahead of the proof. Human trials will determine whether the furnace metaphor holds. The cell’s response to heat is well understood in the laboratory. Whether that response is strong enough to change the course of a chronic degenerative disease in a living human eye is the question that remains.
There is a deeper layer here. The treatment is based on a concept called hormesis. Hormesis is the idea that a mild stressor can strengthen a system. A small dose of something harmful, like heat or radiation, triggers a protective response that makes the system more resilient. This is the same principle behind exercise. Muscle fibers tear slightly during a workout, and the body repairs them stronger than before. The Aalto treatment applies the same logic to the retina. A brief, controlled heat shock triggers repair systems that then remain more active for a period of time.
This is not a new idea in biology. Hormesis has been studied for decades. But applying it to the eye, with the precision required to avoid damage, is new. The researchers had to solve the problem of measuring temperature inside the eye without invasive probes. They used electroretinography, which records the electrical activity of the retina in response to light. The electrical signal changes with temperature, providing a real-time readout. This allowed them to keep the heat within a safe range.
The temperature must stay below 45 degrees Celsius. Above that threshold, tissue damage occurs. The target is a few degrees above normal body temperature, a gentle warmth that signals stress without causing injury. The system is designed to maintain that narrow window.
Other researchers are working on related approaches. At the University of Cambridge, scientists are exploring the use of ultrasound to stimulate cellular repair in the retina[4]. At the National Institutes of Health in the United States, gene therapies are being developed to deliver protective proteins directly to retinal cells[5]. The Aalto method sits alongside these efforts, not in competition. Each approach targets a different point in the disease process. The heat treatment is aimed at the earliest stage, before significant damage has occurred. It is a preventive strategy, not a rescue mission.
The disease itself is staggeringly common. About one third of people over 80 have some form of AMD. In the United States, approximately 20 million adults over 40 are living with the condition. Most of them have the dry form, which progresses slowly but steadily. The numbers are expected to rise as the population ages. A treatment that could slow or halt the early stages would have enormous impact.
The study was funded by Aalto University and other Finnish research organizations[2]. The team includes researchers from the Karolinska Institute in Sweden, which adds an international dimension to the work[3]. The journal paper lists Mooud Amirkavei as the first author, with contributions from Ossi Kaikkonen, Teemu Turunen, Anna Meller, Johanna Ã…hlgren, Anders Kvanta, Helder André, and Ari Koskelainen. The work is a collaboration between physicists, biologists, and ophthalmologists.
The treatment raises questions that go beyond the eye. If a controlled heat shock can activate protective systems in retinal cells, could it work elsewhere? The principle of hormesis is general. It applies to many tissues. But the eye has advantages for this approach. It is accessible to light. The target tissue is close to the surface. The temperature can be monitored through electrical signals. Other organs may not offer the same convenience.
For now, the focus is on the eye. The first human trials will test safety in a small group of patients. If those go well, larger trials will test efficacy. The timeline is uncertain. Three years is optimistic. Regulatory approval takes time. But the direction is clear.
The furnace metaphor holds one more layer. In a forge, metal is heated not to melt it, but to make it malleable. The heat allows the metal to be shaped without breaking. The Aalto treatment applies the same logic to aging cells. The heat does not destroy. It restores flexibility. It allows the cell to reshape its internal environment, to clear out the debris that accumulates with time.
The question that remains is not whether the heat can activate the repair systems. The animal studies have shown that it can. The question is whether that activation is strong enough and sustained enough to make a difference in a human eye over years. The answer will come from the trials.
Ohsumi won his Nobel Prize for discovering a fundamental process. He did not set out to cure a disease. He set out to understand how cells clean themselves. The Aalto team has taken that understanding and turned it into a device. The furnace at the back of the eye is a direct line from a laboratory in Japan to a clinic in Finland, from a basic discovery to an applied technology.
The story is not finished. The trials have not begun. The patients have not been treated. But the path is visible. It leads through the next few years, through safety data and efficacy endpoints, through regulatory reviews and clinical adoption. At the end of that path, if everything works, there will be a new option for millions of people facing the slow loss of their central vision.
The furnace will be warm. The cells will respond. The question is whether the response will be enough.
Sources
1. Nature Communications (2025-10-29)
5. National Institutes of Health
6. FDA
7. Maculaser